<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172392</url>
  </required_header>
  <id_info>
    <org_study_id>2010-019367-11</org_study_id>
    <secondary_id>ANRS HB 06 PEGAN</secondary_id>
    <nct_id>NCT01172392</nct_id>
  </id_info>
  <brief_title>A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B</brief_title>
  <acronym>PEGAN</acronym>
  <official_title>A Randomized, Multicenter, Unblinded, Phase III Study Assessing the Loss of HbsAg at W96 After a 48-week Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (HbeAg Negative) Under Treatment and Responders (Undetectable Viral Load) to a Nucleoside(s) or Nucleotide(s) Analog(s) Treatment for at Least 12 Months. ANRS HB 06 Pegan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the loss of HbsAg after a 48-week pegylated interferon&#xD;
      alpha 2a in patients with chronic hepatitis B (HBeAg negativation)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to provide a therapeutical alternative to the use of an extended&#xD;
      or undeterminated duration of treatment with prolonged nucleoside (s)/nucleotide (s)analog&#xD;
      (s).&#xD;
&#xD;
      The duration of administration is not consensual, and in most cases followed by a virological&#xD;
      relapse, so that, the prolonged use could lead to the occurrence of viral resistance and&#xD;
      mutations.&#xD;
&#xD;
      It is therefore expected that treatment with pegylated interferon for 48 weeks in patients&#xD;
      with undetectable HBV DNA by analog(s) may increase and promotes the loss of HbsAg and then&#xD;
      promotes HbsAg seroconversion. In the absence of cirrhosis, the loss of HbsAg at 6 months&#xD;
      would allow the end of treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbsAg negativation at week 96</measure>
    <time_frame>W96</time_frame>
    <description>Percentage of patients with negative HbsAg at W96, i.e 12 months after a 48 weeks treatment with pegylated interferon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics of HbsAg</measure>
    <time_frame>W-6, W0, W12, W24 and W48</time_frame>
    <description>Kinetics of HbsAg under treatment at W-6, W0, W12, W24 and W48 and after discontinuation of PegIFN alpha 2a at W72, W20 and W144</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <condition>AgHbs Negativation</condition>
  <arm_group>
    <arm_group_label>PegIFN + Nucleosidic or Nucleotidic Analog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nucleosidic or Nucleotidic Analog</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon-alpha-2a</intervention_name>
    <description>180 mcg / wk / SC from D0 to W48</description>
    <arm_group_label>PegIFN + Nucleosidic or Nucleotidic Analog</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleotidic or Nucleosidic Treatment</intervention_name>
    <description>Analog treatment according to investigators practice</description>
    <arm_group_label>Nucleosidic or Nucleotidic Analog</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive Hbs Ag&#xD;
&#xD;
          -  Negative HbeAg&#xD;
&#xD;
          -  Plasma HBV DNA undetectable at pre-inclusion ever since 12 months&#xD;
&#xD;
          -  ALT less than or equal to 5 times the upper limit of normal&#xD;
&#xD;
          -  Non cirrhotic or Not Decompensated Cirrhosis (Child Pugh &lt;7)&#xD;
&#xD;
          -  Undetectable hepatocellular carcinoma in liver scan and / or alpha-fetoprotein rate&#xD;
             &lt;50 ng / ml&#xD;
&#xD;
          -  Unchanged nucleoside (s) and / or nucleotide (s) treatment for at least three months&#xD;
             (and not including telbivudine)&#xD;
&#xD;
          -  Negative pregnancy test for childbearing women&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Use of contraception for childbearing women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polymorphonuclear neutrophils &lt;1500/mm3&#xD;
&#xD;
          -  Platelets &lt;70.000/mm3&#xD;
&#xD;
          -  Co-infections with HIV, HCV and / or HDV&#xD;
&#xD;
          -  Prolonged excessive consumption of alcohol&#xD;
&#xD;
          -  Active intravenous drug addiction&#xD;
&#xD;
          -  Immunomodulators Treatment(eg interferons), ever since one year&#xD;
&#xD;
          -  Immunosuppressive treatments terminated ever since one year&#xD;
&#xD;
          -  Telbivudine treatment&#xD;
&#xD;
          -  Long course steroid treatment (more than 4 weeks) by oral way&#xD;
&#xD;
          -  History of severe epilepsy or current use of anticonvulsants&#xD;
&#xD;
          -  Severe heart disease (eg heart failure stage III or IV NYHA class, myocardial&#xD;
             infarction less than 6 months, ventricular arrhythmia requiring treatment, unstable&#xD;
             angina or other significant cardiovascular disease)&#xD;
&#xD;
          -  Chronic liver disease other than HBV-related (hemochromatosis, autoimmune hepatitis,&#xD;
             metabolic liver disease, including Wilson's disease and a deficiency of&#xD;
             alpha1-antitrypsin deficiency, alcoholic liver disease, exposure to toxins)&#xD;
&#xD;
          -  Presence or suspicion of cancer or a history of cancer (except basal cell carcinoma or&#xD;
             in situ carcinoma) within 5 years preceding the randomization&#xD;
&#xD;
          -  Thyroid uncontrolled disease, abnormal TSH, elevated thyroid antibodies and clinical&#xD;
             manifestations of thyroid dysfunction&#xD;
&#xD;
          -  History of autoimmune disease (inflammatory digestive, idiopathic thrombocytopenic&#xD;
             purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe&#xD;
             psoriasis, rheumatoid arthritis ....) Or presence of autoantibodies at a significant&#xD;
             rate&#xD;
&#xD;
          -  Renal impairment (creatinine clearance &lt;50 ml / min using the Cockroft formula), renal&#xD;
             transplantation, hemodialysis&#xD;
&#xD;
          -  Hypersensitivity to the active substance, interferon alpha or any component&#xD;
&#xD;
          -  History of depression or psychiatric disorders and uncontrolled depression or&#xD;
             uncontrolled psychiatric disorders&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or wish of pregnancy during the study period.&#xD;
&#xD;
          -  Patients under legal protection or unable to express their consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc BOURLIERE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Saint Joseph, Service d'hépatogastroentérologie, Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint Joseph, Service d'hépatogastroentérologie</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>French National Agency for Research on AIDS and viral hepatitis website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

